In recent years, the use of biological agents, such as anti-interleukin (IL)-17, anti-IL-23, and anti-tumor necrosis factor (TNF)-α, has demonstrated considerable success in treating patients with severe PSO [4]; however, these agents can induce adverse events (AEs), such as infection. The gene discussed is TNF; the disease is infection.